絞り込み

17054

広告

「"Chmielowski B "[Author]」の検索結果

98件中 61件~80件表示    検索結果をPubMedで見る PubMedで見る

Adoptive transfer of MART-1 T cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy.

Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma.

Natural killer T cells in advanced melanoma patients treated with tremelimumab.

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.

Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy.

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.

Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors.

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Single-Institution, Multidisciplinary Experience with Surgical Resection of Primary Chest Wall Sarcomas.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway.

KIT as a Therapeutic Target in Metastatic Melanoma.

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Sort by
※並べ替えは表示に時間がかかります